BioCryst公布Orladeyo®(Berotralstat)口服颗粒获得FDA批准,成为唯一的针对2至12岁Hae患者的口服预防治疗
BioCryst公布Orladeyo®(Berotralstat)口服颗粒获得FDA批准,成为唯一的针对2至12岁Hae患者的口服预防治疗
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.